Overview

Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The aim of our study is to investigate whether Rapamune used at a low dose (2 mg/d) retards cyst growth and slows renal functional deterioration in patients with ADPKD.
Phase:
Phase 3
Details
Lead Sponsor:
University of Zurich
Treatments:
Everolimus
Sirolimus